James J. Matera, DO, FACOI, on Comparing NASH and NAFLD
In this video, James Matera, DO, gives a preview of his presentation on the differences between NASH and NAFLD, which will be presented at the Practical Updates in Primary Care 2020 Virtual Series on November 6, 2020.
For more information about PUPC 2020 Virtual Series and to register for upcoming sessions, visit https://practicalupdates.consultant360.com/.
James J. Matera, DO, FACOI, is the Medical Director of Population Health at CentraState Medical Center in Freehold, New Jersey.
James J Matera: I'm Dr. James J Matera. I'm a clinical nephrologist and the Chief Medical Officer at CentraState Medical Center in Freehold, New Jersey. And my topic for the Updates in Primary Care is going to be on the spectrum of NASH and NAFLD.
It's an interesting topic because this came a few years ago when I was giving a talk, and I had a nurse practitioner who started to ask me about cardiovascular complications in this spectrum of diseases. And at that point, we weren't really thinking a lot about this.
I think the spectrum of NASH and NAFLD is quite impressive and that there are a lot of things that are coming out about it. And it's a very important aspect of not only primary care but also cardiovascular care, and overall mortality.
And people sometimes associate NASH and NAFLD as the same disease and they're not quite the same. So one of the things that we'll talk about is some of the differentials of that.
It's going to be very exciting because I'll be looking at some of the treatment options that are available, as well as both the pathological, and radiographic way to diagnose these particular liver entities. And we're also going to talk a fair amount about how much that these diseases can progress into cirrhosis and other liver diseases. So I really look forward to seeing you at the lecture one way or another. And, you know, going over this topic. Look forward to it.